Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%. Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency. Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the alpha-1 antitrypsin deficiency treatment market.
Strategic mergers & acquisitions are also projected to boost alpha-1 antitrypsin deficiency treatment market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.
High unmet medical needs in developing economies are directly providing lucrative opportunities for the alpha-1 antitrypsin deficiency treatment market growth.
The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.
By Route of Administration
By Distribution Channel
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drugs, Route of Administration, Distribution Channel|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Kamada Pharmaceuticals (Israel), CSL Behring LLC (US), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany), AstraZeneca (UK), Vectura Group plc (UK), Pfizer Inc. (US), Mylan Inc. (US)|
|Key Market Opportunities||Increasing R&D expenditure by key players to develop innovative treatment options for AATD|
|Key Market Drivers||
The Alpha-1 Antitrypsin Deficiency Treatment Market was valued at USD 1.4 billion in 2018.
Alpha-1 Antitrypsin Deficiency Treatment Market is expected to exhibit a strong 10.5% CAGR over the forecast period.
Growing awareness about the condition of alpha-1 antitrypsin deficiency is likely to be the major driver for the market.
The Americas dominate the Alpha-1 Antitrypsin Deficiency Treatment Market.
Leading players in the Alpha-1 Antitrypsin Deficiency Treatment Market include Kamada, Pfizer, and Mylan, among others.